| Douglas Tortella, CRNA | |
|
1585 3rd St, Fort Polk, LA 71459-5102 | |
| (337) 531-3011 | |
| Not Available |
| Full Name | Douglas Tortella |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 23 Years |
| Location | 1585 3rd St, Fort Polk, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164459459 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | L6-0A00337 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inspira Medical Center Vineland | Vineland, NJ | Hospital |
| Jefferson Stratford Hospital | Stratford, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Jersey Healthcare Specialists Pc | 2668385253 | 554 |
| Rancocas Anesthesiology Pa | 2769380237 | 88 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
| Entity Name | New Jersey Healthcare Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174585780 PECOS PAC ID: 2668385253 Enrollment ID: O20031110000555 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
| Entity Name | Mid-atlantic Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366486508 PECOS PAC ID: 3779496047 Enrollment ID: O20031112000103 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
| Entity Name | Rancocas Anesthesiology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427076553 PECOS PAC ID: 2769380237 Enrollment ID: O20031222000327 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
| Entity Name | West Jersey Anesthesia Associate Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609861947 PECOS PAC ID: 6507859386 Enrollment ID: O20040407000191 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Douglas Tortella, CRNA 2006 Limestone Rd, Suite 5, Wilmington, DE 19808-5553 Ph: (302) 995-1860 | Douglas Tortella, CRNA 1585 3rd St, Fort Polk, LA 71459-5102 Ph: (337) 531-3011 |
News Archive
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Researchers studying the common genetic disorder chromosome 22q.11 deletion syndrome have identified key proteins that act together to regulate early embryonic development. One protein is essential to life; in animal studies, embryos without the protein do not survive past the first few days of gestation.
A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on May 18, 2010, the Company received a letter from The Nasdaq Stock Market (Nasdaq) indicating that the minimum closing bid price of its common stock had fallen below $1.00 for 30 consecutive trading days, and therefore, A.P. Pharma was not in compliance with Marketplace Rule 5550(a)(2).
Proteostasis Therapeutics announced today that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer's disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease.
› Verified 2 days ago
Anthony Wendell Marcukaitis, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1585 Third St, Fort Polk, LA 71459 Phone: 337-531-3517 | |
Molly Black, Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 210-862-9692 | |
Mr. Douglas Anthony Phillips, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1585 3rd St, Bayne Jones Army Community Hospital, Fort Polk, LA 71459 Phone: 337-531-3344 | |
Mr. Raymond James Devlin Iii, MSN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 16513 Howard St, Apt D, Fort Polk, LA 71459 Phone: 337-537-5375 | |
Marshall Glenister, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 254-760-9499 | |
Travis Husser, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1585 3rd St, Fort Polk, LA 71459 Phone: 985-981-6455 |